Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Enliven Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$33.71

-1.04 (-3%)

D 38Pipeline Score Richly Valued Biotech · Clinical
Market Cap
2.53 B
EPS
-1.66
P/E Ratio
-
Value Trade
24.85 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    20.69 M

  • Operating CF

    -19.29 M

  • Total Assets

    464.85 M

  • Total Liabilities

    11.49 M

  • Equity

    453.37 M

  • D/E Ratio

    12,345

-1.59 %
Week
-10.55 %
1 Month
60.14 %
3 Month
96.31 %
6 Month
32.8 %
5 Year
-25.82 %
All Time
Cash Data
Healthy

  • Cash Position

    452.40 M

  • Monthly Burn

    6.43 M

  • Runway

    69.5 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 7, 2026
Overview
Volume
369.93 K
52 Week Range
14.79 - 48.53
% held by Insiders
22.91 %
% held by Institutions
83.47 %
Enterprise Value
2.08 B
Total Shares
59.33 M
Short %
10.91 %
Float Shares
45.39 M
Company Description
HQ: 6200 LOOKOUT ROAD, BOULDER, CO...
Employees:61
https://www.enliventherapeutic...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout example
ELVN-001 previously treated CP-CML
Phase 1
24%
ELVN-001 is an oral, highly selective active-site BCR::ABL1 inhibitor designed to target chronic myeloid leukemia (CML) at the kinase driver level, demonstrating activity against T315I and resistance-associated mutations. This mechanism distinguishes it from approved ATP-competitive tyrosine kinase inhibitors (TKIs) and allosteric inhibitors such as asciminib, allowing it to be classified as first-in-class rather than me-too or merely best-in-class. The estimated probability of approval (PoA) for ELVN-001 stands at 24.0%. The global market for relapsed or refractory previously treated chronic-phase CML is projected to be between $2 billion and $4 billion. There remains a significant unmet need in this space, particularly for patients who fail or cannot tolerate multiple TKIs, especially those with T315I or multi-resistant disease, as they have limited durable options despite existing therapies. Currently, ELVN-001 is in Phase 1 development, specifically within the ENABLE trial (ELVN-001-101 / NCT05304377), which is an open-label, multicenter Phase 1a/1b dose-escalation and expansion study. This trial is focused on adults with CP-CML who are relapsed, refractory, or intolerant to prior TKIs. The study is actively recruiting and aims to identify recommended expansion doses while assessing safety, pharmacokinetics, and changes in BCR-ABL1 transcript burden. Additionally, a Japan-specific Phase 1 study (NCT06787144) has commenced, although the core evidence base remains anchored in the ENABLE trial. Efficacy data reported thus far are promising but still immature. Publicly available information indicates a major molecular response (MMR) rate of approximately 44% to 47% at 24 weeks, with responses observed even in heavily pretreated patients, including those previously exposed to ponatinib or asciminib. However, as this is a Phase 1 single-arm study, no randomized comparator data or public hazard ratios, p-values, overall survival (OS), or progression-free survival (PFS) metrics are available. Safety data appears favorable, with no maximum tolerated dose (MTD) identified, a lack of clear dose-toxicity relationships, low rates of dose reductions and discontinuations, and a reported 6.4% discontinuation rate due to adverse events in the EHA 2026 update. The primary adverse events noted are hematologic, including thrombocytopenia and neutropenia, with no significant cardiovascular signals reported. In terms of regulatory designations for previously treated CP-CML, ELVN-001 has received orphan drug designation, although there is no public evidence of Fast Track, Breakthrough Therapy, Priority Review, or Accelerated Approval for this specific indication. The competitive landscape for CP-CML is challenging, as multiple effective TKIs and asciminib already address most of the patient population. The unmet need is particularly pronounced in cases of multi-resistant, intolerant, and T315I-mutant disease. Successful precedents in this setting, such as asciminib, have demonstrated the importance of a differentiated mechanism and meaningful activity after prior TKI treatment. Overall, while ELVN-001's PoA is above average for a Phase 1 program due to its targeting of a validated pathway, encouraging early molecular responses, and favorable tolerability, the lack of controlled data and the necessity for durable benefit in a competitive market contribute to the estimate remaining in the mid-20% range. Read More
Small Molecules
Hematologic System
ELVN-001 previously treated CP-CML
Phase 1
24%
ELVN-001 is an oral, highly selective active-site BCR::ABL1 inhibitor designed to target chronic myeloid leukemia (CML) at the kinase driver level, demonstrating activity against T315I and resistance-associated mutations. This mechanism distinguishes it from approved ATP-competitive tyrosine kinase inhibitors (TKIs) and allosteric inhibitors such as asciminib, allowing it to be classified as first-in-class rather than me-too or merely best-in-class. The estimated probability of approval (PoA) for ELVN-001 stands at 24.0%. The global market for relapsed or refractory previously treated chronic-phase CML is projected to be between $2 billion and $4 billion. There remains a significant unmet need in this space, particularly for patients who fail or cannot tolerate multiple TKIs, especially those with T315I or multi-resistant disease, as they have limited durable options despite existing therapies. Currently, ELVN-001 is in Phase 1 development, specifically within the ENABLE trial (ELVN-001-101 / NCT05304377), which is an open-label, multicenter Phase 1a/1b dose-escalation and expansion study. This trial is focused on adults with CP-CML who are relapsed, refractory, or intolerant to prior TKIs. The study is actively recruiting and aims to identify recommended expansion doses while assessing safety, pharmacokinetics, and changes in BCR-ABL1 transcript burden. Additionally, a Japan-specific Phase 1 study (NCT06787144) has commenced, although the core evidence base remains anchored in the ENABLE trial. Efficacy data reported thus far are promising but still immature. Publicly available information indicates a major molecular response (MMR) rate of approximately 44% to 47% at 24 weeks, with responses observed even in heavily pretreated patients, including those previously exposed to ponatinib or asciminib. However, as this is a Phase 1 single-arm study, no randomized comparator data or public hazard ratios, p-values, overall survival (OS), or progression-free survival (PFS) metrics are available. Safety data appears favorable, with no maximum tolerated dose (MTD) identified, a lack of clear dose-toxicity relationships, low rates of dose reductions and discontinuations, and a reported 6.4% discontinuation rate due to adverse events in the EHA 2026 update. The primary adverse events noted are hematologic, including thrombocytopenia and neutropenia, with no significant cardiovascular signals reported. In terms of regulatory designations for previously treated CP-CML, ELVN-001 has received orphan drug designation, although there is no public evidence of Fast Track, Breakthrough Therapy, Priority Review, or Accelerated Approval for this specific indication. The competitive landscape for CP-CML is challenging, as multiple effective TKIs and asciminib already address most of the patient population. The unmet need is particularly pronounced in cases of multi-resistant, intolerant, and T315I-mutant disease. Successful precedents in this setting, such as asciminib, have demonstrated the importance of a differentiated mechanism and meaningful activity after prior TKI treatment. Overall, while ELVN-001's PoA is above average for a Phase 1 program due to its targeting of a validated pathway, encouraging early molecular responses, and favorable tolerability, the lack of controlled data and the necessity for durable benefit in a competitive market contribute to the estimate remaining in the mid-20% range. Read More
Small Molecules
Hematologic System
ELVN-001 previously treated CP-CML
Phase 1
24%
ELVN-001 is an oral, highly selective active-site BCR::ABL1 inhibitor designed to target chronic myeloid leukemia (CML) at the kinase driver level, demonstrating activity against T315I and resistance-associated mutations. This mechanism distinguishes it from approved ATP-competitive tyrosine kinase inhibitors (TKIs) and allosteric inhibitors such as asciminib, allowing it to be classified as first-in-class rather than me-too or merely best-in-class. The estimated probability of approval (PoA) for ELVN-001 stands at 24.0%. The global market for relapsed or refractory previously treated chronic-phase CML is projected to be between $2 billion and $4 billion. There remains a significant unmet need in this space, particularly for patients who fail or cannot tolerate multiple TKIs, especially those with T315I or multi-resistant disease, as they have limited durable options despite existing therapies. Currently, ELVN-001 is in Phase 1 development, specifically within the ENABLE trial (ELVN-001-101 / NCT05304377), which is an open-label, multicenter Phase 1a/1b dose-escalation and expansion study. This trial is focused on adults with CP-CML who are relapsed, refractory, or intolerant to prior TKIs. The study is actively recruiting and aims to identify recommended expansion doses while assessing safety, pharmacokinetics, and changes in BCR-ABL1 transcript burden. Additionally, a Japan-specific Phase 1 study (NCT06787144) has commenced, although the core evidence base remains anchored in the ENABLE trial. Efficacy data reported thus far are promising but still immature. Publicly available information indicates a major molecular response (MMR) rate of approximately 44% to 47% at 24 weeks, with responses observed even in heavily pretreated patients, including those previously exposed to ponatinib or asciminib. However, as this is a Phase 1 single-arm study, no randomized comparator data or public hazard ratios, p-values, overall survival (OS), or progression-free survival (PFS) metrics are available. Safety data appears favorable, with no maximum tolerated dose (MTD) identified, a lack of clear dose-toxicity relationships, low rates of dose reductions and discontinuations, and a reported 6.4% discontinuation rate due to adverse events in the EHA 2026 update. The primary adverse events noted are hematologic, including thrombocytopenia and neutropenia, with no significant cardiovascular signals reported. In terms of regulatory designations for previously treated CP-CML, ELVN-001 has received orphan drug designation, although there is no public evidence of Fast Track, Breakthrough Therapy, Priority Review, or Accelerated Approval for this specific indication. The competitive landscape for CP-CML is challenging, as multiple effective TKIs and asciminib already address most of the patient population. The unmet need is particularly pronounced in cases of multi-resistant, intolerant, and T315I-mutant disease. Successful precedents in this setting, such as asciminib, have demonstrated the importance of a differentiated mechanism and meaningful activity after prior TKI treatment. Overall, while ELVN-001's PoA is above average for a Phase 1 program due to its targeting of a validated pathway, encouraging early molecular responses, and favorable tolerability, the lack of controlled data and the necessity for durable benefit in a competitive market contribute to the estimate remaining in the mid-20% range. Read More
Small Molecules
Hematologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D38
Pipeline Score
$355M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 48%
Small Cap
(rank 472 of 905)
Percentile Rank
Enliven Therapeutics, Inc. faces pipeline headwinds (38/100), with $546M risk-adjusted pipeline value, led by ELVN-002 in HER2 Mutant Non-small Cell Lung Cancer (Phase 1), across $62B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ELVN-002
Small molecule		HER2 Mutant Non-small Cell Lung CancerPhase 1NCT0565087910% $408M ACTIVE NOT_RECRUITING 198 AVERAGE C (45) Jul 1, 2026MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ELVN-001
chronic myeloid leukemia
Phase 1a/1b
2025-11-03
ELVN-001
chronic myeloid leukemia
Phase 1a/1b
2025-11-03
ELVN-001
chronic myeloid leukemia
Phase 1a/1b
2025-11-03
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ELVN
HedgeFund Name
( 3 )
% of Portfolio Current MV
699.84 M (112.69%)
 Shares Owned
17.83 M (-16.54%)
 Activity
Avg Price $0

AFFINITY ASSET ADVISORS, LLC

1.2 % (71.4 %)
23.01 M
586.90 K
46.73% ( 186.90 K)

AFFINITY ASSET ADVISORS, LLC

1.2 % (71.4 %)
23.01 M
586.90 K
46.73% ( 186.90 K)

AFFINITY ASSET ADVISORS, LLC

1.2 % (71.4 %)
23.01 M
586.90 K
46.73% ( 186.90 K)
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ELVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ELVN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ELVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18790 79.00 91990 0 72.13% 2.68% 3.23% - - -
2026-06-18790 79.00 91990 0 72.13% 2.68% 3.23% - - -
2026-06-18790 79.00 91990 0 72.13% 2.68% 3.23% - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
--02.50.2334
--02.50.2334
--02.50.2334
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Enliven Therapeutics, Inc. (ELVN) News & Alerts
-
Monday, June 8, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ELVN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Gastric Cancer #22 of 49 PHASE 1 ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Capecitabine + Eribulin + paclitaxel + Leucovorin
AZN ONC JAZZ
$6.74B 0.82 FOLLOWER
Breast Cancer #31 of 94 PHASE 1 ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Capecitabine + Eribulin + paclitaxel + Leucovorin
MRK AZN GILD
$10.85B 0.85 FOLLOWER
Leukemia #35 of 64 PHASE 1 ELVN-001
AMGN LLY AZN
$4.28B 0.8 FOLLOWER
Colorectal Cancer #36 of 82 PHASE 1 ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Capecitabine + Eribulin + paclitaxel + Leucovorin
ABBV BMY MRK
$7.68B 0.82 FOLLOWER